SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics reports over 3-fold jump in Q4 net profit

12 Apr 2022 Evaluate

Lasa Supergenerics has reported results for fourth quarter and year ended March 31, 2022.

The company has reported over 3-fold jump in its net profit at Rs 12.28 crore for the quarter under review as compared to Rs 3.80 crore for the same quarter in the previous year. Total income of the company increased by 30.96% at Rs 51.22 crore for Q4FY22 as compared Rs 39.11 crore for the corresponding quarter previous year.

For the year ended March 31, 2022, the company has reported net loss of Rs 5.37 crore as compared to net profit of Rs 22.78 crore for the previous year. Total income of the company decreased by 32.24% at Rs 137.18 crore for year under review as compared to Rs 202.44 crore for year ended March 31, 2021.

Lasa Supergenerics Share Price

8.47 0.33 (4.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×